Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Comai

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
European Archives of Psychiatry and Clinical Neuroscience|March 8, 2023
Esmethadone-HCl (REL-1017): a promising rapid antidepressantMaurizio Fava, Stephen M Stahl, Sara De Martin, et al.
International Clinical Psychopharmacology|February 27, 2026
Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressantsClotilde Guidetti, George I Papakostas, Steven Stahl, et al.
The Journal of Clinical Psychiatry|February 25, 2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label StudyMaurizio Fava, Luca Pani, Sara De Martin, et al.
Journal of Clinical Medicine|May 14, 2022
Is Poor Lithium Response in Individuals with Bipolar Disorder Associated with Increased Degradation of Tryptophan along the Kynurenine Pathway? Results of an Exploratory StudyFrederike T Fellendorf, Mirko Manchia, Alessio Squassina, et al.
Pharmacological Research|February 14, 2025
Neuronal PCSK9 regulates cognitive performances via the modulation of ApoER2 synaptic localizationSilvia Pelucchi, Lorenzo Da Dalt, Giulia De Cesare, et al.
Brain : a Journal of Neurology|October 1, 2024
Dopamine neuron dysfunction and loss in the PrknR275W mouse model of juvenile parkinsonismMaria Regoni, Letizia Zanetti, Martina Sevegnani, et al.
The Journal of Clinical Psychiatry|June 25, 2024
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled TrialMaurizio Fava, Stephen M Stahl, Luca Pani, et al.
Frontiers in Psychiatry|November 14, 2024
The clock is ticking on schizophrenia: a study protocol for a translational study integrating phenotypic, genomic, microbiome and biomolecular data to overcome disabilityGiacomo Mercuriali, Lorenzo Lodde, Pasquale Paribello, et al.
Pharmacological Research|November 16, 2023
Melatonin MT<sub>1</sub> receptors as a target for the psychopharmacology of bipolar disorder: A translational studyMargherita Tassan Mazzocco, Claudia Pisanu, Luigi Russo, et al.
Pharmacological Research|December 31, 2025
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and Type 2 Diabetes via 5-HT2B receptor-dependent mechanismsMartina Colognesi, Daniela Gabbia, Anna Signor, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
European Archives of Psychiatry and Clinical Neuroscience|March 8, 2023
Esmethadone-HCl (REL-1017): a promising rapid antidepressantMaurizio Fava, Stephen M Stahl, Sara De Martin, et al.
International Clinical Psychopharmacology|February 27, 2026
Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressantsClotilde Guidetti, George I Papakostas, Steven Stahl, et al.
The Journal of Clinical Psychiatry|February 25, 2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label StudyMaurizio Fava, Luca Pani, Sara De Martin, et al.
Journal of Clinical Medicine|May 14, 2022
Is Poor Lithium Response in Individuals with Bipolar Disorder Associated with Increased Degradation of Tryptophan along the Kynurenine Pathway? Results of an Exploratory StudyFrederike T Fellendorf, Mirko Manchia, Alessio Squassina, et al.
Pharmacological Research|February 14, 2025
Neuronal PCSK9 regulates cognitive performances via the modulation of ApoER2 synaptic localizationSilvia Pelucchi, Lorenzo Da Dalt, Giulia De Cesare, et al.
Brain : a Journal of Neurology|October 1, 2024
Dopamine neuron dysfunction and loss in the PrknR275W mouse model of juvenile parkinsonismMaria Regoni, Letizia Zanetti, Martina Sevegnani, et al.
The Journal of Clinical Psychiatry|June 25, 2024
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled TrialMaurizio Fava, Stephen M Stahl, Luca Pani, et al.
Frontiers in Psychiatry|November 14, 2024
The clock is ticking on schizophrenia: a study protocol for a translational study integrating phenotypic, genomic, microbiome and biomolecular data to overcome disabilityGiacomo Mercuriali, Lorenzo Lodde, Pasquale Paribello, et al.
Pharmacological Research|November 16, 2023
Melatonin MT<sub>1</sub> receptors as a target for the psychopharmacology of bipolar disorder: A translational studyMargherita Tassan Mazzocco, Claudia Pisanu, Luigi Russo, et al.
Pharmacological Research|December 31, 2025
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and Type 2 Diabetes via 5-HT2B receptor-dependent mechanismsMartina Colognesi, Daniela Gabbia, Anna Signor, et al.
Pageof 13